Prime Medicine Inc’s recent filing unveils that its Chief Business Officer Brudnick Richard acquired Company’s shares for reported $23790.0 on May 20 ’25. In the deal valued at $1.19 per share,20,000 shares were bought. As a result of this transaction, Brudnick Richard now holds 20,000 shares worth roughly $33800.0.
Then, LEE ANN L. bought 100,000 shares, generating $113,000 in total proceeds. Upon buying the shares at $1.13, the Chief Technical Officer now owns 100,000 shares.
Before that, Reine Allan bought 125,000 shares. Prime Medicine Inc shares valued at $147,150 were divested by the Chief Executive Officer at a price of $1.18 per share. As a result of the transaction, Reine Allan now holds 125,000 shares, worth roughly $0.21 million.
Citigroup downgraded its Prime Medicine Inc [PRME] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid May from “an Overweight” to “a Neutral”. H.C. Wainwright also remained covering PRME and has decreased its forecast on May 20, 2025 with a “Neutral” recommendation from previously “Buy” rating. JMP Securities started covering the stock on December 10, 2024. It rated PRME as “a Mkt outperform”.
Price Performance Review of PRME
On Friday, Prime Medicine Inc [NASDAQ:PRME] saw its stock jump 24.26% to $1.69. Over the last five days, the stock has gained 43.22%. Prime Medicine Inc shares have fallen nearly -42.12% since the year began. Nevertheless, the stocks have fallen -73.80% over the past one year. While a 52-week high of $8.14 was reached on 01/06/25, a 52-week low of $1.11 was recorded on 05/22/25. SMA at 50 days reached $1.4458, while 200 days put it at $2.7936.
Levels Of Support And Resistance For PRME Stock
The 24-hour chart illustrates a support level at 1.4900, which if violated will result in even more drops to 1.2900. On the upside, there is a resistance level at 1.8000. A further resistance level may holdings at 1.9100. The Relative Strength Index (RSI) on the 14-day chart is 62.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1663, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 3.33%. Stochastics %K at 63.51% indicates the stock is a holding.
The most recent change occurred on May 20, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
